Next Article in Journal
Discovery of Novel Pleuromutilin Derivatives as Potent Antibacterial Agents for the Treatment of MRSA Infection
Previous Article in Journal
Preliminary Study of Resistance Mechanism of Botrytis cinerea to SYAUP-CN-26
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 3
10.3390/molecules27030938
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Fibrous Roots of Cimicifuga Are at Risk of Hepatotoxicity

by
Yang Yu
1,
Jialiang Tan
1,
Jianing Nie
1,
Chongning Lv
1,2,* and
Jincai Lu
1,2,*
1
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110006, China
2
Liaoning Provincial Key Laboratory of TCM Resources Conservation and Development, Shenyang Pharmaceutical University, Shenyang 110006, China
*
Authors to whom correspondence should be addressed.
Molecules 2022, 27(3), 938; https://doi.org/10.3390/molecules27030938
Submission received: 29 December 2021 / Revised: 26 January 2022 / Accepted: 27 January 2022 / Published: 29 January 2022
Browse Figures
Review Reports Versions Notes

Abstract

:
The cause of liver damage by using black cohosh preparation has been concerned but remains unclear. After a preliminary investigation, the black cohosh medicinal materials sold in the market were adulterated with Asian cohosh (Cimicifuga) without removing the fibrous roots. The safety of Cimicifuga rhizome and fibrous roots is unknown and has not been reported. Therefore, in this paper, the rhizome and fibrous roots of Cimicifuga dahurica (Turcz.) Maxim (C. dahurica) were completely separated, extracted with 70% ethanol, and freeze-dried to obtain crude rhizome extract (RC) and fibrous roots extract (FRC). UHPLC-Q-TOF-MS was used to identify 39 compounds in the rhizome and fibrous roots of Cimicifuga, mainly saponins and phenolic acids. In the L-02 cytotoxicity experiment, the IC50 of fibrous roots (1.26 mg/mL) was slightly lower than that of rhizomes (1.417 mg/mL). In the 90-day sub-chronic toxicity study, the FRC group significantly increased the level of white blood cells, ALP, ALT, AST, BILI and CHOL (p < 0.05); large area of granular degeneration and balloon degeneration occurred in liver tissue; and the expression of p-NF-kB in the nucleus increased in a dose-dependent manner. Overall, Fibrous roots of Cimicifuga are at risk of hepatotoxicity and should be strictly controlled and removed during the processing.

Graphical Abstract

1. Introduction

Black cohosh extract can produce estrogen-like effects and regulate endocrine balance, so it is widely used as a hormone replacement and an anti-inflammatory agent for the treatment of menopausal syndrome. Since around 2000, clinical cases of liver injury caused by taking black cohosh extract appeared successively in Australia, the United States and European countries [1,2,3,4]. However, according to the current study, the cause of liver injury caused by black cohosh preparation has not been found [5,6,7,8]. With the shortage of black cohosh resources, some herbs similar to black cohosh have been adulterated into the medicinal material market. Many Asian species of cohosh (Cimicifuga foetida, C. dahurica and C. heracleifolia) are sold as black cohosh [9].
The Asian species of cohosh-cimicifuga has a long history of medicinal use in Asian countries such as China, Japan and Korea [10]. The main chemical constituents of Cimicifuga are triterpenoid glycosides, Phenylpropanes, nitrogenous compounds and chromones [11]. Among them, saponins have the functions of regulating immunity, protecting the brain and heart, delaying aging, antitumor, expanding cerebral vessels and increasing blood flow [12,13]. Phenylpropanoids have antitumor, anti-HIV, antioxidant, anti-inflammatory, anti-microbial, anticoagulant and other biological activities. Some phenylpropanoids also have the effects of lowering blood lipid, blood pressure, blood glucose, antithrombotic, antimutagenic, analgesia and sedation [14]. Alkaloids have anti-inflammatory, antibacterial, vasodilator, cardiotonic, anti-asthmatic, anticancer and other effects [15]. Similar to black cohosh, it is also used to relieve menopausal symptoms [16].
Cimicifuga has been used in China for thousands of years, and no clinical cases of liver injury have been reported so far. We found that the processing method of Cimicifuga in the Chinese Pharmacopoeia clearly stipulates “removal of soil, sun-drying, singe or remove the fibrous roots”. While in the west, there was no such operation in the preparation of black cohosh. In addition, our previous studies found that the chemical composition and content of Cimicifuga rhizome and fibrous roots were different, and cimicifugone A and B isolated from fibrous roots of cimicifuga may have hepatotoxicity.
Therefore, it is necessary to comprehensively evaluate the toxicity of the rhizome and fibrous roots of cimicifuga. In this study, UHPLC-Q-TOF-MS was used to identify the main chemical components, and the hepatotoxicity was evaluated by the cytotoxicity test on normal human hepatocytes (L-02) in vitro and the 90-day sub-chronic toxicity test in vivo.

2. Results and Discussion

2.1. Identification of the Chemical Compositions by UHPLC-Q-TOF-MS

In order to identify the main chemical components of cohosh, firstly, a comprehensive search and classification of the compounds of cimicifuga species was carried out in the Scifinder database, and a potential database was initially established. Then, by comparing the retention time and the accurate relative molecular mass, the structure of the detected chemical composition is determined. In addition, we combined our laboratory’s previous experience in the isolation and identification of cimicifuga and summarized the fragmentation regularities of these compounds by mass spectrometry [10,17,18]; some compounds were determined by comparison with the mass spectrometry data of the reference substance. Figure 1 shows the UHPLC-Q-TOF-MS base peak intensity chromatograms of the rhizomes and fibrous roots of C. dahurica in positive and negative electrospray (ESI) modes. Finally, 52 compounds in the rhizome extract (RC) and fibrous roots extract (FRC) of C. dahurica were analyzed. The corresponding mass spectra data are listed in Table 1 and Table 2. The analysis results showed that the main chemical components of the rhizomes and fibrous roots of C. dahurica are all saponin and phenolic acid compounds, in addition to a small number of alkaloids.

2.2. Cytotoxicity Results of L-02 Cells

In the in vitro cytotoxicity test, the MTT method was used to detect the effects of the RC and FRC of C. dahurica on the viability of normal human liver cells L-02. RC and FRC have no obvious inhibitory effect on the proliferation of L-02 cells, but it is worth noting that the IC50 of the FRC (1260 μg/mL) is slightly lower than the IC50 value of the RC (1417 μg/mL), suggesting that the fibrous roots may have a higher potential for hepatotoxicity than the rhizome.

2.3. General Observation and Body Weight

During the whole experiment period, the weight of female and male rats changed normally, and there was no significant difference between the treatment groups and the control group (Figure 2). The diet and water intake of each group were normal. However, it is worth noting that a total of six rats died during the experiment, of which the mortality rate of the fibrous roots group and rhizome group was 5:1, while the death ratio of female and male rats was 2:1. These results suggested that the toxicity risk of fibrous roots was significantly higher than rhizome, and the females were more easily damaged than males.

2.4. Urinalysis, Hematology and Biochemical Analysis

The results of urinalysis are shown in Table 3. No dose-related adverse reactions were observed in any administration group of female and male rats. There are some slight gaps in various test indicators, but these changes are sporadic and within the acceptable range of normal physiology.
The results of the hematology test are shown in Table 4. For female rats, compared with the control group, the white blood cell (WBC) level of each dose group of FRC was significantly increased (p < 0.05), but there was no significant difference in the RC group. For male rats, only the FRC-UHD group had a significant increase in WBC (p < 0.01). As the “guard” of the human body’s fight against diseases, WBC can deform and pass through the capillary wall to concentrate on the invasion site of the disease, enveloping and swallowing the disease [19,20]. The number of WBC in the body is higher than the normal value, so it is likely that the body has inflammation. Hematological test results show that long-term use of fibrous roots is likely to cause inflammation, and females are more sensitive than males.
The results of serum biochemical analysis are shown in Table 5. Compared with the control group, there was no significant difference in the biochemical indicators of the RC groups (p > 0.05). Yun [21] selected the crude extract of the rhizome of Cimicifuga heracleifolia Kom. for 13 weeks of safety evaluation, and the biochemical test results showed that the changes in various indicators are sporadic and within physiologically acceptable ranges. This is consistent with the results of the rhizome of C. dahurica in this study, suggesting that the rhizome part of Cimicifuga is safe and will not cause physical lesions under normal clinical doses.
The FRC groups had a significant increase in Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in female rats (p < 0.05), and the content of ALT increased significantly (p < 0.001) in the FRC-UHD group. ALT and AST are important clinical indicators of liver function tests to determine whether the liver is damaged [22,23]. It can be seen from the test results that long-term use of FRC extract may cause liver damage, thereby increasing the content of AST in the blood. At the same time, it may be accompanied by a biliary obstruction, leading to ALT excretion obstacles and backflow into the blood, making the serum ALT content significantly increased. At the same time, for male rats, the FRC-UHD group also showed a significant increase in Alkaline phosphatase (ALP) and ALT levels (p < 0.001). ALP is excreted through the hepatobiliary system. When the liver is damaged or impaired, liver cells over-produce ALP and enter the blood through the lymphatic tract and sinusoids, causing high levels of ALP in serum [24,25].
Most of the body’s bilirubin (TBIL) comes from hemoglobin released by the lysis of senescent red blood cells, including indirect and direct bilirubin. Total gallbladder = direct bilirubin + indirect bilirubin. Indirect bilirubin is transported to the liver through the blood, and direct bilirubin is produced through the action of hepatocytes [26]. The total bilirubin content in the blood of male rats after administration of fibrous roots was generally higher than that in the control group, and the FRC-UHD group was statistically significant (p < 0.05). It is suggested that the liver of rats after taking fibrous roots is damaged, and the process of direct bilirubin transport through the blood to the liver will be correspondingly inhibited, thereby increasing the total bilirubin content in the blood. Total cholesterol (CHOL) includes free cholesterol and cholesterol esters. The liver is the main organ for cholesterol synthesis and storage, and its serum concentration can be used as an indicator of lipid metabolism [27]. The total cholesterol content of the FRC-UHD group was significantly higher than that of the blank group, and the female rats were significantly (p < 0.01) higher than that of the male rats (p < 0.05). It is suggested that excessively high doses of fibrous roots are likely to cause damage to the liver of rats, leading to obstruction of bile excretion, increasing the synthesis of blood lipoproteins and cholesterol in the liver, and increasing free cholesterol, leading to high total cholesterol.
In addition, for male rats, the urea nitrogen (UREA) and creatinine (CREA) of the fibrous roots administration group increased to varying degrees but did not show a dose dependence. When the kidney’s ability to eliminate and excrete decreases, it will also lead to an increase in blood urea nitrogen, which is often accompanied by an increase in blood creatinine [28]. This suggests that the fibrous roots of C. dahurica may also cause slight damage to the kidneys.

2.5. Organ Weights and Histopathological Changes

The organ weights and organ coefficients are shown in Table 6. By comparing the absolute and relative organ weights of the main organs of rats in each dose group of RC and FRC, it was found that there was no significant difference compared with the control group (p > 0.05). Visual observation of the organs showed that the RC group and the FRC group were similar in volume, color and shape to the control group, and there was no obvious damage or pathology.
Histopathological examination of the liver (Figure 3) found that the liver tissue sections of the female and male rats in the control group were basically normal. The liver tissue envelope was composed of dense connective tissue rich in elastic fibers. The liver lobules were clearly demarcated and arranged regularly. The central part of the hepatic lobule is the central vein, surrounded by roughly radially arranged liver cells and hepatic sinusoids. The liver cells are round and full, the liver plates are arranged regularly and neatly and the sinusoids are not significantly expanded or squeezed. The portal area between adjacent liver lobules has no obvious abnormalities and no obvious inflammatory changes. Compared with the control group, the liver tissue sections of each dose of the RC administration group showed no significant difference, and this is consistent with the research report of Mazzanti [7]. Mazzanti conducted morphological tests on liver samples after oral administration of black cohosh extract to Wistar rats for 30 days, and the results showed that black cohosh extract had no significant effect on the liver morphology of rats. However, in the liver tissues of the FRC-MD and FRC-HD groups, a large number of granular degeneration of hepatocytes, swelling of the cells, loose cytoplasm and a fine granular shape were seen (yellow arrows). In the FRC-UHD group, a large number of balloon-like degeneration of hepatocytes, swelling of the cells, centered nucleus and vacuolation of the cytoplasm were seen in the tissues of the FRC-UHD group (Black arrows). It is suggested that fibrous roots of C. dahurica caused liver tissue lesions.

2.6. Effect on Protein Expression of p-NF-κB

This study explored the molecular mechanism of drug-induced liver injury by detecting the expression of p-NF-κB in the nucleus of rat liver tissue. Western blot results are shown in Figure 4. In the control group, p-NF-κB was almost not expressed. Compared with the control group, there was no statistical difference in the expression of p-NF-κB in the RC group at the dose of this experiment (p > 0.05), but there was still a small amount of protein expression in the liver cells of female rats, suggesting that long time exposure or an increased dose may lead to increased risk of hepatotoxicity to female. In accordance with the above experimental results, the expression of p-NF-κB in the hepatic nuclei of both male and female rats was significantly increased in the FRC group (p < 0.01) in a dose-dependent manner. In addition, the expression of p-NF -κB in female rats was significantly higher than that in male rats. NF-κB is a heterodimer combined with inactivated inhibitory protein (IκB). It is located in the cytoplasm and is an important transcription factor in the process of inflammation. Long-term administration of cohosh root causes liver damage and inflammation in rats, which activates the phosphorylation of NF-κB and transfers to the nucleus, increasing the expression of p-NF -κB in the nucleus of rats. The p-NF -κB activates specific target genes through transcription, e.g., inflammatory mediators such as cytokines, chemokines, cell adhesion molecules, etc. [29,30]. This translocation is the mechanism by which cells respond to oxidants or inflammatory and immune stimuli. It suggests that the fibrous roots of C. dahurica can cause liver tissue damage in rats and trigger inflammation.

3. Materials and Methods

3.1. Plant Material and Animals

C.dahurica was purchased from the Shenyang medicine market in China and authenticated by Prof. Jin-cai Lu (School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University). The medicinal material specimens are stored in the Department of Traditional Chinese Medicine Resources of Shenyang Pharmaceutical University (No. 2019102301). We artificially separate the rhizomes and fibrous roots when C. dahurica is fresh and cut them into small pieces after sun-drying. Then, they were extracted with 70% ethanol at a factory, concentrated and freeze-dried. (The extraction yield of the alcohol extraction of RC was 0.32 g/g, and the extraction yield of the alcohol extraction of FRC was 0.29 g/g).

3.2. Identification of Chemical Compositions in Crude Extract

Using Compact™ QTOF mass spectrometry (Bruker Daltonik GmbH, Bremen, Germany) and elution autosampler UHPLC system tandem technology (Bruker Daltonik GmbH, Bremen, Germany), the crude extracts of rhizomes and fibrous roots of C. dahurica were qualitatively analyzed in positive and negative electrospray (ESI) mode at m/z 50–1300. A Waters Acquity BEH C18 column (2.1 × 100 mm, 1.7 μm) (Waters Corp., Milford, MA, USA) was used. The mobile phase consisted of water-formic acid (100:0.1, v/v) (A) and acetonitrile (B). The injection volume was 1 μL, and the flow rate was 0.3 mL/min. The column temperature was maintained at 35 °C. The optimized gradient elution conditions for UHPLC are: 15~25% B in 0~10 min, 25~40% B in 10~15 min, 40~47% B in 15~25 min and 25~26 min within 47~15% B. The instrument parameters used for mass spectrometry are as follows: At 1.8 Bar, 220 °C and a flow rate of 8.0 L/min, and nitrogen is used as the nebulizer gas. Collision energy values: 100 m/z, 20 eV; 500 m/z, 30 eV; 1000 m/z, 50 eV; and m/z 1300, 55 eV. All data were collected and processed using Bruker Compass data analysis 5.1 software (Bruker Daltonik GmbH, Bremen, Germany).

3.3. In Vitro Hepatocyte Toxicity Test

After resuscitation, human normal hepatocytes L-02 were cultured in a DMEM medium containing 10% fetal bovine serum and 1% double antibody. As for the cells, they were cultured in an incubator at 37 °C and 5% CO2 at saturated humidity. The cell density grew. When it reaches 70–80%, trypsin was added to digest and pass it down to a new cell culture dish. The L-02 cells in the logarithmic growth phase were seeded in a 96-well plate at 5 × 103 cells/well, with 100 μL of cell culture medium per well. The 96-well plate was placed in an incubator for about 12 h to adhere to the cell wall and then starved for another 12 h. Then, the serum-free culture medium replaced with different concentrations of drugs (100, 200, 400, 800, 1600 μg/mL). For the medium of drug RC or FRC and 2% serum, the control group was replaced with an equal volume of 2% serum-containing culture medium and returned to the incubator to continue culturing for 72 h. After the culture plate was removed, we added μL of MTT working solution to each well and incubated it in the incubator for 4 h. Then, all the liquid in the wells was aspirated; 150 μL of DMSO was added to each well to dissolve the crystals; the culture plate was placed on a shaker and shook for 10 min to fully dissolve the crystals. We used a multifunctional microplate reader to detect the absorbance (OD) value at a 492 nm wavelength. The experiment was repeated three times [30]. Finally, we calculated the cell survival rate according to the following formula and used SPSS 19.0 software to calculate the IC50 value of the drug. Calculated as follows:
Inhibition rate of cell proliferation (%) = (1 − OD administration group/OD control group) × 100%.

3.4. Experimental Design for the Oral Toxicity Study

One hundred and eight Special pathogen-free (SPF) Sprague Dawley rats (aged 4~8 weeks, weight 165 ± 15 g) were provided by the Experimental Animal Center of Shenyang Pharmaceutical University (Shenyang, China), and they were used after a week of quarantine and acclimatization. Animals were housed in an SPF laboratory under controlled temperatures (25 ± 1 °C), humidity (60 ± 10%) conditions and a 12 h light/dark cycle, and they were allowed free access to a balanced murine diet and water during the experiment (Lab Diet 5002 Certified Rodent Diet). All of the animal experiments were approved by the Institutional Animal Care and Use Committee of the Biomedical Research Institute at the Shenyang Pharmaceutical University and complied with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978). Combined with the previous acute toxicity experiment and the clinical dosage of cimicifuga, the dosage for the 90-day repeated administration toxicity experiment was determined. The sample of RC and FRC was Orally administered (10 mL/kg) to rats (6/sex/group) at doses of 0.585 g/kg (LD), 1.755 g/kg (MD), 5.265 g/kg (HD) and 15.795 g/kg (UHD), and the normal control group was given vehicle (0.5% CMC-Na solution) once a day. During the experiment, we observed the test animals’ general clinical symptoms, food and water consumption and mortality every day. Additionally, we measured their body weight once a week.

3.5. Urinalysis, Hematology and Biochemistry Analysis

In the last week of treatment, fresh urine samples of 10 rats (5 males and 5 females) were taken from each group and analyzed with a urine analyzer (URIT-500B, Guangxi, China) to evaluate the following parameters: WBC, KET, NIT, URO, BIL, PRO, GLU, SG, BLD, pH and Vc.
The rats were anesthetized with isoflurane after the final gavage. Blood samples are collected through the posterior vena cava. Collect the whole blood sample into the EDTA blood collection tube. Use the automatic hematology analyzer ADVIA 2120i hematology counter (Siemens, Germany) to perform hematology determination of the following parameters: WBC, RBC, HGB, HCT, PLT, MCV, MCH, MCHC, neutrophils, eosinophils, basophils, lymphocytes, monocytes and reticulocytes.
For the biochemical analysis, whole blood was separated at 3000 rpm for 15 min, and serum was separated immediately. Measured with automatic biochemical analyzer 7020 (Hitachi, Tokyo, Japan): ALP, ALT, AST, BUN, CREA, TBIL, GLU, TC, TG, TP, ALB.

3.6. Gross Findings, Organ Weights, and Histopathological Assessments

During necropsy, the organs and tissues were observed macroscopically, and the absolute weight of the heart, liver, spleen, lung, kidney, stomach, brain, adrenal gland, thymus and genitalia were recorded, and the relative weight (organ-to-body weight ratios) was calculated.
Part of the liver tissue (2.0 cm × 2.0 cm × 0.3 cm) was taken and fixed in 4% paraformaldehyde solution, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Then, use an optical microscope for pathological examination to analyze whether there are histological changes in the liver of each group of rats.

3.7. Western Blot Analysis

We collected 60mg liver samples of rats in each experimental group and extracted nuclear protein according to the instructions of the nuclear protein extraction kit. The protein concentration was determined by the bicinchoninic acid (BCA) method. Equal protein samples were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (Bio-Rad, Hercules, CA, USA) and electro transferred onto polyvinylidene difluoride (PVDF) membranes for 2 h. The membranes were incubated for 1 h with 5% skim milk in the Tris-buffered saline containing Tween 20 to block nonspecific binding. After incubating at room temperature for 1 h, the blocking solution was discarded, and the primary antibodies of Phospho-NF-κB p65 (3033, 1:1000) and β-actin (4970, 1:1000) (Cell Signaling Technology, Danvers, MA, USA) were added to the membranes, which were incubated at 4 °C overnight and then washed with Tris buffered saline (TBS) containing 0.1% Tween-20 (TBST) buffer for 3 × 10 min. The secondary antibodies Anti-rabbit IgG (7074, 1:1000) (Cell Signaling Technology, Danvers, MA, USA) were added and incubated for 2 h at room temperature, after washing three times with TBST, and developed with enhanced chemiluminescence (ECL) developer and exposed to X-ray film. The expression levels of β-actin were used as control.

3.8. Statistical Analysis

All of the values are expressed as mean ± SD. The statistical analysis was performed using a one-way ANOVA, followed by a multiple comparison procedure with a Tukey/Duncan test using SPSS software version 19.0 (IBM corporation, Armonk, NY, USA). p values of less than 0.05 were considered to be statistically significant. The figures were conducted using GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA).

4. Conclusions

This study found that the rhizome of C. dahurica was safe to take for a long time under the dose of 15.795 g/kg crude drug a day in rats. (It is equivalent to 177 g/d of clinical intake for adults with a weight of about 70 kg.) Additionally, there were no obvious toxic and side effects. However, there is a risk of liver damage in the long-term high-dose administration of C. dahurica fibrous roots since with an increase in the dose, the number of white blood cells in the blood increases significantly, and the biochemical test shows ALP, ALT, AST, BILI and CHOL all have a significant increase, and the expression of p-NF-κB is also significantly increased, which are all landmark indicators of liver damage. This result explains the rationality and necessity of removing fibrous roots in the processing method of cimicifuga. In addition, the material basis of hepatotoxicity of Cimicifuga fibrous roots remains to be further studied.

Author Contributions

Conceptualization, Y.Y., C.L. and J.L.; data curation, Y.Y.; formal analysis, Y.Y. and J.N.; funding acquisition, J.L.; investigation, J.N.; methodology, Y.Y.; project administration, J.L.; software, Y.Y. and J.T.; supervision, C.L. and J.L.; validation, J.T.; writing—original draft, Y.Y.; writing—review and editing, C.L. and J.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Scientific Research Fund of Liaoning Provincial Education Department of China (No. 2017LQN09) and the National Natural Science Foundation of China (Grant No. U1508220).

Institutional Review Board Statement

The animal study protocol was approved by the Institutional Animal Care and Use Committee of the Biomedical Research Institute at the Shenyang Pharmaceutical University (protocol code: SYPU-IACUC-S2018-04.09-201, and the date of approval was 9 April 2018). The HL-7702[L-02] cell line was originally thought to originate from a normal fetal liver. and the L-02 cells used in our experiments were provided by FuHeng Bio Co., Ltd. (product ID: FH0109).

Informed Consent Statement

Not applicable.

Data Availability Statement

This article has fully reflected all the data of this study.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of cimicifuga rhizome and fibrous roots crude extracts are available from the authors.

References

  1. Enbom, E.T.; Le, M.D.; Oesterich, L.; Rutgers, J.; French, S.W. Mechanism of hepatotoxicity due to black cohosh (Cimicifuga racemosa): Histological, immunohistochemical and electron microscopy analysis of two liver biopsies with clinical correlation. Exp. Mol. Pathol. 2014, 96, 279–283. [Google Scholar] [CrossRef] [PubMed]
  2. Teschke, R.; Schwarzenboeck, A. Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): Critical analysis and structured causality assessment. Phytomedicine 2009, 16, 72–84. [Google Scholar] [CrossRef] [PubMed]
  3. Fabio, F.; Luigi, G.; Paolo, R.D.S. Black Cohosh Hepatic Safety: Follow-Up of 107 Patients Consuming a Special Cimicifuga racemosa rhizome Herbal Extract and Review of Literature. Evid.-Based Compl. Alt. 2011, 2011, 821392. [Google Scholar] [CrossRef] [Green Version]
  4. Lim, T.Y.; Considine, A.; Quaglia, A.; Shawcross, D.L. Subacute liver failure secondary to black cohosh leading to liver transplantation. BMJ Case Rep. 2013, 2013, bcr2013009325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. He, C.C.; Dai, Y.Q.; Hui, R.R.; Hua, J.; Chen, H.J.; Luo, Q.Y.; Li, J.X. NMR-based metabonomic approach on the toxicological effects of a Cimicifuga triterpenoid. J. Appl. Toxicol. 2012, 32, 88–97. [Google Scholar] [CrossRef] [PubMed]
  6. Lude, S.; Torok, M.; Dieterle, S.; Knapp, A.C.; Kaeufeler, R.; Jaggi, R.; Spornitz, U.; Krahenbuhl, S. Hepatic effects of Cimicifuga racemosa extract in vivo and in vitro. Cell. Mol. Life Sci. 2007, 64, 2848–2857. [Google Scholar] [CrossRef]
  7. Mazzanti, G.; Di Sotto, A.; Franchitto, A.; Mastrangelo, S.; Pezzella, M.; Vitalone, A.; Mammola, C.L. Effects of Cimicifuga racemosa extract on liver morphology and hepatic function indices. Phytomedicine 2008, 15, 1021–1024. [Google Scholar] [CrossRef]
  8. Naser, B.; Schnitker, J.; Minkin, M.J.; de Arriba, S.G.; Nolte, K.U.; Osmers, R. Suspected black cohosh hepatotoxicity: No evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause 2011, 18, 366–375. [Google Scholar] [CrossRef]
  9. Mahady, G.B.; Low Dog, T.; Barrett, M.L.; Chavez, M.L.; Gardiner, P.; Ko, R.; Marles, R.J.; Pellicore, L.S.; Giancaspro, G.I.; Sarma, D.N. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008, 15 Pt 1, 628–638. [Google Scholar] [CrossRef]
  10. Qin, R.-L.; Lv, C.-N.; Zhao, Y.; Zhao, Y.-D.; Yu, Y.; Lu, J.-C. Assessment of phenolics contents and antioxidant properties in Cimicifuga dahurica (Turcz.) Maxim during drying process. Ind. Crops Prod. 2017, 107, 288–296. [Google Scholar] [CrossRef]
  11. Guo, Y.; Yin, T.; Wang, X.; Zhang, F.; Pan, G.; Lv, H.; Wang, X.; Owoicho Orgah, J.; Zhu, Y.; Wu, H. Traditional uses, phytochemistry, pharmacology and toxicology of the genus Cimicifuga: A review. J. Ethnopharmacol. 2017, 209, 264–282. [Google Scholar] [CrossRef] [PubMed]
  12. Jia, H.; Wang, X.; Liu, W.; Qin, X.; Hu, B.; Ma, Q.; Lv, C.; Lu, J. Cimicifuga dahurica extract inhibits the proliferation, migration and invasion of breast cancer cells MDA-MB-231 and MCF-7 in vitro and in vivo. J. Ethnopharmacol. 2021, 277, 114057. [Google Scholar] [CrossRef] [PubMed]
  13. Wu, L.; Chen, Z.-L.; Su, Y.; Wang, Q.-H.; Kuang, H.-X. Cycloartenol triterpenoid saponins from Cimicifuga simplex (Ranunculaceae) and their biological effects. Chin. J. Nat. Med. 2015, 13, 81–89. [Google Scholar] [CrossRef]
  14. Lu, Q.; Zhang, W.-Y.; Pan, D.-B.; Shi, D.-F.; Pang, Q.-Q.; Li, H.-B.; Yao, X.-J.; Yao, Z.-H.; Yu, Y.; Yao, X.-S. Phenolic acids and their glycosides from the rhizomes of Cimicifuga dahurica. Fitoterapia 2019, 134, 485–492. [Google Scholar] [CrossRef]
  15. Lourenço, A.M.; Máximo, P.; Ferreira, L.M.; Pereira, M.M.A. Indolizidine and quinolizidine alkaloids structure and bioactivity. In Studies in Natural Products Chemistry; Attaur, R., Ed.; Elsevier: Amsterdam, The Netherlands, 2002; Volume 27, pp. 233–298. [Google Scholar]
  16. Miao, L.-Y.; Chu, T.T.H.; Li, P.; Jiang, Y.; Li, H.-J. Cimicifuga heracleifolia is therapeutically similar to black cohosh in relieving menopausal symptoms: Evidence from pharmacological and metabolomics studies. Chin. J. Nat. Med. 2019, 17, 435–445. [Google Scholar] [CrossRef]
  17. Fan, M.; Qin, K.; Ding, F.; Huang, Y.; Wang, X.; Cai, B. Identification and differentiation of major components in three different “Sheng-ma” crude drug species by UPLC/Q-TOF-MS. Acta Pharm. Sin. B 2017, 7, 185–192. [Google Scholar] [CrossRef] [PubMed]
  18. Hu, L.; Song, X.; Nagai, T.; Yamamoto, M.; Dai, Y.; He, L.; Kiyohara, H.; Yao, X.; Yao, Z. Chemical profile of Cimicifuga heracleifolia Kom. And immunomodulatory effect of its representative bioavailable component, cimigenoside on Poly(I:C)-induced airway inflammation. J. Ethnopharmacol. 2021, 267, 113615. [Google Scholar] [CrossRef]
  19. Bain, B.J. Structure and function of red and white blood cells and platelets. Medicine 2021, 49, 183–188. [Google Scholar] [CrossRef]
  20. Parente, J. Diagnostics for White Blood Cell Abnormalities: Leukocytosis and Leukopenia. Physician Assist. Clin. 2019, 4, 625–635. [Google Scholar] [CrossRef]
  21. Yun, J.-W.; You, J.-R.; Kim, Y.-S.; Cho, E.-Y.; Kim, S.-H.; Yoon, J.-H.; Kwon, E.; Chung, D.H.; Kim, Y.T.; Jang, J.-J.; et al. Pre-clinical in vitro and in vivo safety evaluation of Cimicifuga heracleifolia. Regul. Toxicol. Pharm. 2015, 73, 303–310. [Google Scholar] [CrossRef]
  22. Xie, K.; Chen, C.H.; Tsai, S.P.; Lu, P.J.; Wu, H.; Zeng, Y.; Ye, Y.; Tu, H.; Wen, C.; Huang, M.; et al. Loss of Life Expectancy by 10 Years or More From Elevated Aspartate Aminotransferase: Finding Aspartate Aminotransferase a Better Mortality Predictor for All-Cause and Liver-Related than Alanine Aminotransferase. Am. J. Gastroenterol. 2019, 114, 1478–1487. [Google Scholar] [CrossRef] [PubMed]
  23. Xu, J.; Xia, Y.; Li, S.; Cheng, X.; Hu, S.; Gao, Y.; Zhou, X.; Wang, G.; Zheng, Q. A retrospective pilot study to examine the potential of aspartate aminotransferase to alanine aminotransferase ratio as a predictor of postoperative acute kidney injury in patients with hepatocellular carcinoma. Ann. Clin. Biochem. 2019, 56, 357–366. [Google Scholar] [CrossRef] [PubMed]
  24. Lee, T.H.; Kim, W.R.; Poterucha, J.J. Evaluation of Elevated Liver Enzymes. Clin. Liver Dis. 2012, 16, 183–198. [Google Scholar] [CrossRef] [PubMed]
  25. Siddique, A.; Kowdley, K.V. Approach to a Patient with Elevated Serum Alkaline Phosphatase. Clin. Liver Dis. 2012, 16, 199–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. McDaniel, M.J. Hepatic Function Testing: The ABCs of the Liver Function Tests. Physician Assist. Clin. 2019, 4, 541–550. [Google Scholar] [CrossRef]
  27. Domínguez-Pérez, M.; Simoni-Nieves, A.; Rosales, P.; Nuño-Lámbarri, N.; Rosas-Lemus, M.; Souza, V.; Miranda, R.U.; Bucio, L.; Uribe Carvajal, S.; Marquardt, J.U.; et al. Cholesterol burden in the liver induces mitochondrial dynamic changes and resistance to apoptosis. J. Cell. Physiol. 2019, 234, 7213–7223. [Google Scholar] [CrossRef] [PubMed]
  28. Manoeuvrier, G.; Bach-Ngohou, K.; Batard, E.; Masson, D.; Trewick, D. Diagnostic performance of serum blood urea nitrogen to creatinine ratio for distinguishing prerenal from intrinsic acute kidney injury in the emergency department. BMC Nephrol. 2017, 18, 173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Mckay, L.I.; Cidlowski, J.A. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: Mechanisms of mutual antagonism. Mol. Endocrinol. 1998, 12, 45–56. [Google Scholar] [CrossRef] [Green Version]
  30. Tak, P.P.; Firestein, G.S. NF-kappaB: A key role in inflammatory diseases. J. Clin. Investig. 2001, 107, 7–11. [Google Scholar] [CrossRef]
Molecules 27 00938 g001 550
Figure 1. UHPLC-Q-TOF-MS base peak intensity chromatograms of C. dahurica. (a) rhizome of C. dahurica in negative mode; (b) rhizome of C. dahurica in positive mode; (c) fibrous roots of C. dahurica in negative mode; (d) fibrous roots of C. dahurica in positive mode.
Figure 1. UHPLC-Q-TOF-MS base peak intensity chromatograms of C. dahurica. (a) rhizome of C. dahurica in negative mode; (b) rhizome of C. dahurica in positive mode; (c) fibrous roots of C. dahurica in negative mode; (d) fibrous roots of C. dahurica in positive mode.
Molecules 27 00938 g001
Molecules 27 00938 g002 550
Figure 2. Effects of rhizome and fibrous roots of C. dahurica on the body weight changes after oral administration in male and female rats for 90 days: 0.585 g/kg (LD), 1.755 g/kg (MD), 5.265 g/kg (HD) and 15.795 g/kg (UHD). Data expressed as means ± SD.
Figure 2. Effects of rhizome and fibrous roots of C. dahurica on the body weight changes after oral administration in male and female rats for 90 days: 0.585 g/kg (LD), 1.755 g/kg (MD), 5.265 g/kg (HD) and 15.795 g/kg (UHD). Data expressed as means ± SD.
Molecules 27 00938 g002
Molecules 27 00938 g003 550
Figure 3. Effects of rhizome and fibrous roots of C. dahurica on histopathological changes after oral administration in male and female rats for 90 days. Hematoxylin–Eosin stain, 200×.
Figure 3. Effects of rhizome and fibrous roots of C. dahurica on histopathological changes after oral administration in male and female rats for 90 days. Hematoxylin–Eosin stain, 200×.
Molecules 27 00938 g003
Molecules 27 00938 g004 550
Figure 4. Effect of rhizome and fibrous roots of C. dahurica on the expression of p-NF-κB Protein in the liver after oral administration in male and female rats for 90 days. (a) p-NF-κB and β-actin protein electrophoresis images of female rats. (b) p-NF-κB/β-actin column charts of female rats. (c) p-NF-κB and β-actin protein electrophoresis images of male rats. (d) p-NF-κB/β-actin column charts of male rats. Data were expressed as means ± SD (n = 3). ** p < 0.01; *** p < 0.001.
Figure 4. Effect of rhizome and fibrous roots of C. dahurica on the expression of p-NF-κB Protein in the liver after oral administration in male and female rats for 90 days. (a) p-NF-κB and β-actin protein electrophoresis images of female rats. (b) p-NF-κB/β-actin column charts of female rats. (c) p-NF-κB and β-actin protein electrophoresis images of male rats. (d) p-NF-κB/β-actin column charts of male rats. Data were expressed as means ± SD (n = 3). ** p < 0.01; *** p < 0.001.
Molecules 27 00938 g004
Table
Table 1. Characterization of compounds identified from rhizome of C. dahurica by UHPLC-Q-TOF-MS.
Table 1. Characterization of compounds identified from rhizome of C. dahurica by UHPLC-Q-TOF-MS.
NO.tR (min)Measured Mass
(m/z)		Extraction Mass (m/z)FormulaError (ppm)Fragment Ions
(m/z)		Identified Compounds
11.10 271.0454 [M − H]−271.0459 C11H12O81.9 253.0340, 181.0497, 123.0458Fukiic acid
21.21 315.1079 [M − H]−315.1085 C14H20O82.1 153.0566, 123.0451Cimidahurinine
31.24 255.0506 [M − H]−255.0510 C11H12O7 1.8 193.0487, 179.0334, 165.0553Piscidic acid
41.85 315.1097 [M − H]−315.1085 C14H20O8−3.7153.0542, 123.0441Cimidahurine
52.08 379.0985 [M + Na]+379.1000 C16H20O93.8 177.0530 cis-Ferulic acid-4-O-β-d-gal
62.12 379.0982 [M + Na]+379.1000 C16H20O94.8 177.0529 trans-Ferulic acid-4-O-β-d-gal
72.19 179.0348 [M − H]−179.0350 C9H8O40.9 135.0454 Caffeic acid
84.09 476.1902 [M + H]+476.1915 C24H29NO92.7 314.1370, 177.0524trans-feruloyl tyramine-4-O-β-d-glu
94.12 193.0501 [M − H]−193.0506 C10H10O42.9 178.0231, 134.0359Ferulic acid
104.17 193.0509 [M − H]−193.0506 C10H10O4−1.2178.0244, 134.0368Isoferulic acid
114.23 307.1163 [M + H]+307.1176 C16H18O64.2 289.1053, 259.0590, 235.0583Cimifugin
124.36457.0719 [M + Na]+457.0741 C20H18O114.8 295.0396, 163.0372Cimicifugic acid G
134.73 433.0769 [M − H]−433.0776 C20H18O111.7 271.0450, 179.0344, 135.0452Fukinolic acid
144.81 506.2011 [M + H]+506.2021 C25H31NO101.9 344.1466, 177.0532Isocimicifugamide
154.83 506.2003 [M + H]+506.2021 C25H31NO103.5 344.1456, 177.0530Cimicifugamide
166.07441.0755 [M + Na]+411.0792 C20H18O103.4 279.0453, 163.0378Cimicifugic acid D
6.25 417.0813 [M − H]−417.0827 3.5 179.0342, 135.0447,
177.39471.0865 [M + Na]+471.0898 C21H20O113.3 295.0390, 177.0525Cimicifugic acid A
7.47 447.0916 [M − H]−447.0933 3.9 253.0341, 181.0499, 165.0556, 109.0286
187.94471.0864 [M + Na]+471.0898 C21H20O123.3 295.0398, 177.0528Cimicifugic acid B
8.01 447.0912 [M − H]−447.0933 4.6 253.0343, 181.0496, 165.0544, 109.0288
198.92485.1025 [M + Na]+485.1054 C22H22O113.0 279.0461, 207.06232-isoferuloyl fukinolic acid-1-melyl esier
9.12 461.1083 [M − H]−461.1089 1.4 253.0601, 193.0499, 165.0547, 149.0607
209.39455.0918 [M + Na]+455.0949 C21H20O103.1 279.0453, 177.05332-feruloyl-piscidic acid
9.55 431.0974 [M − H]−431.0984 2.3 237.0396, 193.0494, 165.0544
219.86 431.0969 [M − H]−431.0984 C21H20O103.5 237.0395, 193.0491, 165.05432-isoferuloyl-piscidic acid
9.88455.0919 [M + Na]+455.0949 3.0 279.0458, 177.0524
2210.99485.1034 [M + Na]+485.1054 C22H22O112.1 279.0432, 207.06012-feruloyl-fukinolic acid-1-melyl esier
11.37 461.1085 [M − H]−461.1089 0.9 253.0339, 181.0503, 109.0280
2312.94367.076 [M + Na]+367.0788 C18H16O72.8 299.4364, 177.06674′-methoxyl-3′-hydroxy-carboxy benzoyl isoferulic acid anhyelride
13.07 343.0814 [M − H]−343.0823 2.8 193.0497, 134.0364
2413.52 657.3595 [M + Na]+657.3609 C35H54O102.2 617.3627, 467.311612β-O-7,8-Didehydroxycimigenol-3-O-β-d-xyl
2513.59 659.3772 [M + Na]+659.3766 C35H56O10−0.9619.3786, 487.3391, 469.3289(22R)-22β-Hydroxycimigenol-3-O-β-d-xyl
2614.32 703.3993 [M + Na]+703.4028 C37H60O115.0 663.4060, 645.3944, 513.3543, 495.3408, 453.3217 24-epi-O-Acetylhydrosheng manol-3-O-β-ara
2714.47 701.3843 [M + Na]+701.3871 C37H58O114.0 679.4008, 661.3910, 601.3685, 451.317612β-Acetylcimigenol-3-O-β-d-xyl
2814.99745.3728 [M + Na]+745.3770 C38H58O134.5 745.3728Cimilactone K
2915.57 198.0916 [M − H]−198.0924 C13H13NO4.4 198.0916 (E)-3-(3-methyl-2-butenylidene)-2-indolinone
3015.59 198.0922 [M − H]−198.0924 C13H13NO1.3 198.0922 (Z)-3-(3-methyl-2-butenylidene)-2-indolinone
3116.16787.3830 [M + Na]+787.3875 C40H60O144.8 585.3597, 435.315924-epi-24-O-Acetyl-7,8-didehydroshengmanol-3-O-(2′-O-malonyl)-β-d-xyl
3216.70 635.3796 [M − H]−635.3801 C35H56O100.8 577.3356 7β-Hydroxycimigenol-3-O-β-D-xyl
3316.92 637.3948 [M − H]−637.3957 C35H58O101.5 579.3510 Beesioside E
3417.09 679.4091 [M − H]−679.4063 C37H60O11−4.1619.3796 24-O-acetylhydro-shengmanol-3-O-β-d-xyl
3517.61643.3798 [M + Na]+643.3817 C35H56O91.8 585.3713, 435.3190Cimigenol-3-O-β-d-xyl (Cimigenoside)
3618.06683.3700 [M + Na]+683.3766 C37H56O104.9 643.3609, 435.328825-O-Acetyl-7,8-didehydrocimigenol-3-O-β-d-xyl
3718.08 635.3789 [M − H]−635.3801 C35H56O101.8 577.3359 12β-hydroxycimigenol-3-O-α-L-ara
3818.26643.3790 [M + Na]+643.3817 C35H56O92.7 585.3726, 435.3295Cimigenol-3-O-α-L-ara (Cimiracemoside C)
3918.30 637.3957 [M − H]−637.3957 C35H58O100.1 579.3521 Beesioside B
4018.40703.3967 [M + Na]+703.4028 C37H60O112.7 645.3944, 513.354424-epi-24-O-Acetylhydroshengmanol-3-O-β-d-xyl
4118.76 679.4069 [M − H]−679.4063 C37H60O11−1.0619.3770 24-O-acetylhydroshengmanol-3-O-β-D-xyl
4218.83701.3828 [M + Na]+701.3871 C37H58O114.5 451.3172, 274.271624-O-Acetyl-7,8-didehydro-hydroshengmanol-3-O-β-d-xyl
4319.11 707.3979 [M − H]−707.4012 C38H60O124.7 661.3903, 619.3691, 469.357024-Epi-24-O-acetyl-7,8-dehydro cohosh alcohol-3-O-β-d-gal
4421.77 659.3785 [M − H]−659.3801 C37H56O102.4 617.3720, 559.319827-Deoxy Arcot hormone
4521.97 661.3938 [M − H]−661.3957 C37H58O102.9 619.3715, 601.358323-O-Acetyl alcohol cimicifuga-3-O-β-xyl
4622.11511.3374 [M + Na]+511.3394 C30H48O51.9 453.334224-epi-Cimigenol
4722.18 677.3889 [M − H]−677.3906 C37H58O112.6 617.3732 7,8-Deoxy cohosh alcohol-24-O-acetylalcohol-ara
4822.45511.3368 [M + Na]+511.3394 C30H48O52.6 435.3219 Cimigenol
4923.56 665.3882 [M − H]−665.3906 C36H58O113.7 619.3203 12β-Hydroxy cohosh alcohol-3-O-β-d-gal
5024.56863.4360 [M + Na]+863.4400 C43H68O163.9 803.7323, 643.3770, 572.4235, 435.3229Heracleifolinoside F
5124.82569.3434 [M + Na]+569.3449 C32H50O71.5 529.3466, 511.3389 24-O-Acetyl-7,8-didehydro-hydroshengmanol
5225.12571.3590 [M + Na]+571.3605 C32H52O71.5 513.3530, 453.335224-O-Acetylhydroshengmanol
Table
Table 2. Characterization of compounds identified from fibrous roots of C. dahurica by UHPLC-Q-TOF-MS.
Table 2. Characterization of compounds identified from fibrous roots of C. dahurica by UHPLC-Q-TOF-MS.
NO.tR (min)Measured Mass
(m/z)		Extraction Mass (m/z)FormulaError (ppm)Fragment Ions
(m/z)		Identified Compounds
11.07 271.0457 [M − H]−271.0459 C11H12O80.8 253.0379, 181.0493, 123.0428Fukiic acid
21.12 315.1079 [M − H]−315.1085 C14H20O82.0 153.0553, 123.0437Cimidahurinine
31.16 255.0507 [M − H]−255.0510 C11H12O7 1.8 193.0467, 179.0293, 165.0559Piscidic acid
41.19 315.1082 [M − H]−315.1085 C14H20O81.1 153.0560, 123.0433Cimidahurine
52.00 379.0991 [M + Na]+379.1000 C16H20O92.4 177.0541cis-Ferulic acid-4-O-β-d-gal
62.15 379.0990 [M + Na]+379.1000 C16H20O92.6 177.0537trans-Ferulic acid-4-O-β-d-gal
72.17 179.0350 [M − H]−179.0350 C9H8O4−0.1135.0431Caffeic acid
84.00 476.1899 [M + H]+476.1915 C24H29NO93.5 314.1380, 177.0548trans-feruloyl tyramine-4-O-β-d-glu
94.33 457.0734 [M + Na]+457.0741 C20H18O111.7 295.0406, 163.0382Cimicifugic acid G
104.39 307.1167 [M + H]+307.1176 C16H18O63.0 289.1044, 259.0595, 235.0592Cimifugin
114.39 433.0758 [M − H]−433.0776 C20H18O114.3 271.0476, 179.0342, 135.0449 Fukinolic acid
124.40 193.0503 [M − H]−193.0506 C10H10O41.7 178.0308, 134.0359Ferulic acid
134.46 506.2009 [M + H]+506.2021 C25H31NO102.2 344.1520, 177.0540Isocimicifugamide
144.52 193.0497 [M − H]−193.0506 C10H10O44.7 178.0261, 134.0380Isoferulic acid
154.69 506.2006 [M + H]+506.2021 C25H31NO102.8 344.1492, 177.0557Cimicifugamide
166.06 441.0783 [M + Na]+411.0792 C20H18O102.2 279.0482,163.0377Cimicifugic acid D
6.07 417.0821 [M − H]−417.0827 1.5 255.0465, 193.0519, 179.0347
177.27 447.0920 [M − H]−447.0933 C21H20O112.8 253.0341, 181.0495, 165.0538, 109.0294Cimicifugic acid A
7.37 471.0896 [M + Na]+471.0898 0.4 295.0435, 177.0549
187.87 471.0895 [M + Na]+471.0898 C21H20O120.5 295.0417, 177.0548Cimicifugic acid B
7.88 447.0918 [M − H]−447.0933 3.3 253.0348, 181.0500, 165.0550, 109,0291
198.91 461.1077 [M − H]−461.1089 C22H22O112.7 165.0536, 193.0495, 233.06242-isoferuloyl fukinolic acid-1-melyl esier
8.92 485.1059 [M + Na]+485.1054 −1.0279.0494, 207.0615
209.35 455.0941 [M + Na]+455.0949 C21H20O101.6 367.0784, 279.04612-feruloyl-piscidic acid
9.40 431.0978 [M − H]−431.0984 1.4 237.0418, 193.0560, 165.0560
219.74 431.0964 [M − H]−431.0984 C21H20O104.6 237.0398, 193.0500, 165.05482-isoferuloyl-piscidic acid
9.87 455.0947 [M + Na]+455.0949 0.3 279.0473, 177.0547
2211.29 485.1047 [M + Na]+485.1054 C22H22O111.5 279.0456, 207.06722-feruloyl-fukinolic acid-1-melyl esier
11.41 461.1072 [M − H]−461.1089 3.8 253.0352, 181.0496, 109.0289
2312.90 343.0809 [M − H]−343.0823 C18H16O74.1 193.0499, 134.03634′-methoxyl-3′-hydroxy-carboxy benzoyl isoferulic acid anhyelride
12.92 367.0768 [M + Na]+367.0788 2.7 299.4364,177.0667
2413.48 657.3593 [M + Na]+657.3609 C35H54O102.4 617.3645, 467.312912β-O-7,8-Didehydroxycimigenol-3-O-β-d-xyl
2513.70 659.3736 [M + Na]+659.3766 C35H56O104.5 451.3189, 177.0521(22R)-22β-Hydroxycimigenol-3-O-β-d-xyl
2613.76 703.4055 [M + Na]+703.4028 C37H60O11−3.9663.4041, 645.3946, 513.3544, 495.3244, 453.328024-epi-O-Acetylhydrosheng manol-3-O-β-ara
2715.18 198.0920 [M − H]−198.0924 C13H13NO2.5 198.0913(E)-3-(3-methyl-2-butenylidene)-2-indolinone
2815.24 701.3838 [M + Na]+701.3871 C37H58O114.8 679.4007, 661.3891, 601.3702, 451.315812β-Acetylcimigenol-3-O-β-d-xyl
2915.26 198.0924 [M − H]−198.0924 C13H13NO0.4 198.0924(Z)-3-(3-methyl-2-butenylidene)-2-indolinone
3015.89 745.3764 [M + Na]+745.3770 C38H58O130.7 671.3720, 513.3649, 435.3291Cimilactone K
3116.24 787.3838 [M + Na]+787.3875 C40H60O144.7 647.3384, 526.3150, 429.297824-epi-24-O-Acetyl-7,8-didehydroshengmanol-3-O-(2′-O-malonyl)-β-d-xyl
3216.44 635.3794 [M − H]−635.3801 C35H56O101.1 577.33567β-Hydroxycimigenol-3-O-β-D-xyl
3317.30 637.3927 [M − H]−637.3957 C35H58O104.7 579.3483Beesioside E
3417.37 643.3786 [M + Na]+643.3817 C35H56O93.8 585.3712, 435.3242Cimigenol-3-O-β-d-xyl (Cimigenoside)
3517.52 679.4043 [M − H]−679.4063 C37H60O112.9 619.37724-O-acetylhydro-shengmanol-3-O-β-d-xyl
3617.79 635.3777 [M − H]−635.3801 C35H56O103.7 577.335212β-hydroxycimigenol-3-O-α-l-ara
3718.06 683.3731 [M + Na]+683.3766C37H56O105.0 511.3385, 453.336925-O-Acetyl-7,8-didehydrocimigenol-3-O-β-d-xyl
3818.09 637.3928 [M − H]−637.3957 C35H58O104.6 579.3481Beesioside B
3918.28 643.3803 [M + Na]+643.3817 C35H56O92.0 585.3746, 435,3225Cimigenol-3-O-α-l-ara (Cimiracemoside C)
4018.42 703.4001 [M + Na]+703.4028 C37H60O113.8 645.3962, 513.355824-epi-24-O-Acetylhydroshengmanol-3-O-β-d-xyl
4118.81 701.3828 [M + Na]+701.3871 C37H58O115.4 451.321024-O-Acetyl-7,8-didehydro-hydroshengmanol-3-O-β-d-xyl
4219.17 679.4031 [M − H]−679.4063 C37H60O114.7 619.378424-O-acetylhydroshengmanol-3-O-β-d-xyl
4319.63 707.3988 [M − H]−707.4012 C38H60O123.4 661.3891, 619.3727, 469.334124-Epi-24-O-acetyl-7,8-dehydro cohosh alcohol-3-O-β-D-gal
4420.15 659.3770 [M − H]−659.3801 C37H56O102.4 617.3614, 559.327627-Deoxy Arcot hormone
4521.92 661.3937 [M − H]−661.3957 C37H58O113.0 619.3892, 601.347623-O-Acetyl alcohol cimicifuga-3-O-β-xyl
4621.96511.3379 [M + Na]+511.3394 C30H48O52.9 453.3355, 471.3932 24-epi-Cimigenol
4723.19 511.3396 [M + Na]+511.3394 C30H48O5−0.5453.3340, 435.3219 Cimigenol
4823.39 677.3897 [M − H]−677.3906 C37H58O111.4 617.36857,8-Deoxy cohosh alcohol-24-O-acetylalcohol-ara
4923.61 665.3908 [M − H]−665.3906 C36H58O11−0.3619.382512β-Hydroxy cohosh alcohol-3-O-β-d-gal
5024.62 643.3783 [M + Na]+643.3817 C35H56O95.2 529.3487, 453.3347Cimiaceroside B
5124.92 569.3432 [M + Na]+569.3449 C32H50O72.9 529.3481, 511.344224-O-Acetyl-7,8-didehydro-hydroshengmanol
5225.55 571.3580 [M + Na]+571.3605 C32H52O74.4 531.3659, 453.334424-O-Acetylhydroshengmanol
Table
Table 3. Urinalysis of rats with 90-day repeated administration of rhizome and fibrous roots of C. dahurica.
Table 3. Urinalysis of rats with 90-day repeated administration of rhizome and fibrous roots of C. dahurica.
GroupControlRCFRC
0LDMDHDUHDLDMDHDUHD
Females
WBC (Cell/μL)---------
KET (mmol/L)---------
NIT---------
URO (μmol/L)NormalNormalNormalNormalNormalNormalNormalNormalNormal
BIL (μmol/L)---------
PRO (g/L)+3+3+2+3+3+3+3+3+2
GLU---------
SG1.0051.0051.0101.0051.0051.0051.0101.0101.020
BLD (Cell/μL)---------
pH7.57.57.57.57.57.57.57.57.0
Vc (mmol/L)±±-±±±±±±
Males
WBC (Cell/μL)---------
KET (mmol/L)---------
NIT---------
URO (μmol/L)NormalNormalNormalNormalNormalNormalNormalNormalNormal
BIL (μmol/L)---------
PRO (g/L)+3+3+3+3+3+2+3+3+2
GLU---------
SG1.0051.0051.0101.0051.0051.0051.0051.0101.015
BLD (Cell/μL)---------
pH7.57.07.57.57.57.07.57.07.0
Vc (mmol/L)±±±±±±±±±
Rhizome extract (RC), fibrous roots extract (FRC), 0.585 g/kg (LD), 1.755 g/kg (MD), 5.265 g/kg (HD), 15.795 g/kg (UHD), White blood cells (WBC), ketone bodies (KET), nitrite (NIT), urine bilirubin (URO), bil-irubin (BIL), protein (PRO), glucose (GLU), specific gravity (SG), hemoglobin (BLD) and Vitamin C (Vc).
Table
Table 4. Hematological analysis of rats with 90-day repeated administration of rhizome and fibrous roots of C. dahurica.
Table 4. Hematological analysis of rats with 90-day repeated administration of rhizome and fibrous roots of C. dahurica.
GroupControlRCFRC
0LDMDHDUHDLDMDHDUHD
Females
WBC (109 cells/L) 7.4 ± 0.36.8 ± 0.67.2 ± 1.07.9 ± 1.45.2 ± 0.510.5 ± 1.3 *10.3 ± 0.6 *10.4 ± 0.7 **10.9 ± 1.2 **
RBC (1012 cells/L)6.9 ± 0.76.2 ± 0.36.4 ± 0.56.4 ± 0.66.5 ± 0.26.7 ± 1.06.1 ± 0.36.9 ± 0.46.5 ± 1.1
HGB (g/L) 131.7 ± 8.3130.5 ± 8.6129.2 ± 9.6126.4 ± 10.4124.8 ± 4.5132.5 ± 9.7124.3 ± 6.0138.0 ± 3.7128.0 ± 14.9
HCT (%) 43.6 ± 2.042.6 ± 1.943.1 ± 2.442.1 ± 2.742.0 ± 2.144.2 ± 2.442.1 ± 2.243.9 ± 2.444.6 ± 1.8
PLT (1011 cells/L) 13.2 ± 1.512.4 ± 0.814.3 ± 1.112.0 ± 1.213.9 ± 2.511.6 ± 2.411.6 ± 1.111.9 ± 1.811.9 ± 2.7
MCV (fL) 65.6 ± 2.068.4 ± 1.067.7 ± 1.566.3 ± 2.564.7 ± 2.666.3 ± 2.468.6 ± 1.867.0 ± 2.067.1 ± 2.2
MCH (pg)19.2 ± 1.021.0 ± 0.320.3 ± 0.519.9 ± 0.419.3 ± 0.420.6 ± 0.720.3 ± 0.420.1 ± 0.719.7 ± 0.9
MCHC (g/L) 301.7 ± 5.5306.0 ± 7.3300.0 ± 6.9300.0 ± 6.2297.5 ± 5.3299.8 ± 6.6295.8 ± 3.9299.2 ± 4.2298.6 ± 5.0
Neutrophils (%) 11.1 ± 1.710.8 ± 4.411.3 ± 4.311.4 ± 2.614.2 ± 3.115.5 ± 5.215.9 ± 4.217.5 ± 5.518.9 ± 3.4
Eosinophils (%) 2.3 ± 0.22.6 ± 0.81.5 ± 0.22.2 ± 1.12.8 ± 0.43.4 ± 0.93.3 ± 1.02.2 ± 0.22.1 ± 0.3
Basophils (%)0.5 ± 0.20.5 ± 0.10.4 ± 0.20.5 ± 0.30.5 ± 0.10.5 ± 0.10.3 ± 0.10.5 ± 0.20.4 ± 0.2
Lymphocytes (%) 76.8 ± 12.888.1 ± 3.886.0 ± 4.485.1 ± 3.271.2 ± 13.075.4 ± 10.278.9 ± 3.985.2 ± 6.683.3 ± 2.9
Monocytes (%) 0.9 ± 0.50.5 ± 0.10.7 ± 0.30.7 ± 0.20.7 ± 0.10.9 ± 0.10.8 ± 0.20.8 ± 0.20.7 ± 0.2
Reticulocytes (%)12.1 ± 2.313.8 ± 1.712.0 ± 1.411.7 ± 2.510.7 ± 0.814.9 ± 1.710.4 ± 0.812.1 ± 1.811.5 ± 1.5
Males
WBC (109 cells/L) 7.4 ± 1.08.5 ± 1.28.8 ± 0.69.0 ± 0.98.9 ± 0.68.8 ± 1.09.0 ± 0.39.5 ± 0.510.4 ± 1.0 **
RBC (1012 cells/L)6.8 ± 0.77.8 ± 0.57.9 ± 0.37.6 ± 0.47.5 ± 0.67.0 ± 1.47.4 ± 0.67.3 ± 0.77.7 ± 0.2
HGB (g/L) 146.0 ± 4.4149.0 ± 5.3143.7 ± 2.3141.5 ± 3.7137.3 ± 5.1142.0 ± 4.6141.7 ± 4.6144.7 ± 5.8141.7 ± 5.7
HCT (%) 42.1 ± 2.047.0 ± 2.647.8 ± 0.346.6 ± 1.845.9 ± 2.148.4 ± 3.147.6 ± 4.147.4 ± 3.947.4 ± 2.2
PLT (1011 cells/L) 12.0 ± 1.812.1 ± 1.513.0 ± 1.514.2 ± 1.711.7 ± 1.711.0 ± 1.512.1 ± 1.911.2 ± 1.111.2 ± 1.5
MCV (fL) 60.6 ± 1.360.5 ± 1.660.4 ± 2.461.0 ± 1.661.2 ± 2.064.2 ± 4.364.7 ± 4.364.8 ± 1.665.1 ± 3.9
MCH (pg)18.6 ± 1.318.7 ± 0.418.2 ± 0.418.6 ± 0.618.4 ± 0.920.4 ± 1.719.7 ± 1.119.3 ± 0.518.6 ± 0.4
MCHC (g/L) 299.0 ± 5.6309.2 ± 4.7301.3 ± 6.4309.3 ± 6.4294.5 ± 5.2308.5 ± 2.6304.7 ± 5.0297.7 ± 1.2296.3 ± 3.5
Neutrophils (%) 14.6 ± 2.117.9 ± 3.316.2 ± 2.717.2 ± 1.717.8 ± 5.717.6 ± 3.815.1 ± 5.020.0 ± 7.219.3 ± 6.3
Eosinophils (%) 4.8 ± 1.13.4 ± 1.62.7 ± 1.33.1 ± 1.92.4 ± 1.22.7 ± 1.82.4 ± 0.63.7 ± 1.23.4 ± 1.1
Basophils (%)0.3 ± 0.10.6 ± 0.20.4 ± 0.10.4 ± 0.10.5 ± 0.10.6 ± 0.10.6 ± 0.20.5 ± 0.40.4 ± 0.2
Lymphocytes (%) 74.5 ± 6.972.0 ± 12.379.7 ± 2.275.4 ± 6.376.1 ± 7.276.6 ± 5.880.7 ± 4.879.6 ± 5.580.6 ± 2.2
Monocytes (%) 1.0 ± 0.30.8 ± 0.50.9 ± 0.10.8 ± 0.31.1 ± 0.21.2 ± 1.01.0 ± 0.60.8 ± 0.20.8 ± 0.2
Reticulocytes (%)6.8 ± 1.57.6 ± 0.87.8 ± 0.59.0 ± 2.29.6 ± 1.49.8 ± 1.99.7 ± 2.19.7 ± 0.79.9 ± 2.3
Total white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), platelets (PLT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC). * Significantly different from Control group (p < 0.05). ** Significantly different from Control group (p < 0.01).
Table
Table 5. Biochemical analysis of rats with 90-day repeated administration of rhizome and fibrous roots of C. dahurica.
Table 5. Biochemical analysis of rats with 90-day repeated administration of rhizome and fibrous roots of C. dahurica.
GroupControlRCFRC
0LDMDHDUHDLDMDHDUHD
Females
ALP (U/L)38.2 ± 9.033.7 ± 10.635.9 ± 11.936.3 ± 11.834.3 ± 12.439.8 ± 10.332.4 ± 6.539.9 ± 7.241.0 ± 11.1
ALT (U/L)34.8 ± 2.542.5 ± 4.842.7 ± 3.742.4 ± 5.442.8 ± 5.246.0 ± 6.2 **39.3 ± 2.843.0 ± 6.0 *63.1 ± 8.4 ***
AST (U/L)182.1 ± 28.1168.9 ± 17.7174.5 ± 23.2208.5 ± 56.7215.7 ± 42.4248.0 ± 42.4 *237.7 ± 41.4 *227.3 ± 67.5185.5 ± 20.5
UREA (mmol/L)6.7 ± 0.56.2 ± 0.46.5 ± 0.67.1 ± 0.46.9 ± 0.47.3 ± 0.78.0 ± 0.7 **7.4 ± 0.77.5 ± 0.9
CREA (Umol/L)25.8 ± 2.226.9 ± 6.225.2 ± 2.426.5 ± 2.025.9 ± 4.528.1 ± 4.327.4 ± 6.827.6 ± 2.029.0 ± 6.5
TBIL (Umol/L)5.8 ± 1.75.4 ± 1.46.1 ± 1.45.7 ± 1.06.4 ± 1.16.1 ± 1.45.7 ± 0.95.9 ± 1.45.6 ± 1.4
GLU (mmol/L)3.0 ± 0.23.3 ± 0.73.3 ± 0.43.3 ± 0.42.8 ± 0.33.0 ± 0.62.9 ± 0.52.8 ± 0.73.6 ± 0.5
CHOL (mmol/L)2.0 ± 0.21.8 ± 0.21.8 ± 0.21.9 ± 0.11.9 ± 0.32.0 ± 0.22.2 ± 0.22.2 ± 0.22.5 ± 0.3 **
TG (mmol/L)0.6 ± 0.10.5 ± 0.10.5 ± 0.10.6 ± 0.10.6 ± 0.00.6 ± 0.00.6 ± 0.10.6 ± 0.10.5 ± 0.0
TP (g/L)60.7 ± 4.757.7 ± 2.861.0 ± 5.363.0 ± 2.663.2 ± 3.763.7 ± 2.563.1 ± 1.965.4 ± 3.069.4 ± 5.0
ALB (g/L)39.7 ± 2.740.4 ± 3.540.8 ± 2.541.0 ± 1.241.4 ± 2.341.7 ± 0.940.7 ± 0.941.8 ± 1.444.7 ± 2.7
Males
ALP (U/L)58.9 ± 9.769.8 ± 12.466.8 ± 14.371.0 ± 8.257.1 ± 11.368.2 ± 17.758.4 ± 8.864.3 ± 9.690.8 ± 3.4 ***
ALT (U/L)42.0 ± 7.055.1 ± 8.448.1 ± 6.152.5 ± 2.045.5 ± 6.054.9 ± 9.348.6 ± 4.748.5 ± 8.080.4 ± 11.9 ***
AST (U/L)201.2 ± 11.4241.5 ± 71.7202.1 ± 33.7234.8 ± 51.0148.1 ± 54.8262.7 ± 35.8216.2 ± 32.4192.1 ± 48.4194.3 ± 35.7
UREA (mmol/L)5.4 ± 0.36.2 ± 0.76.0 ± 0.46.2 ± 0.46.0 ± 0.77.2 ± 0.4 ***6.3 ± 0.7 *6.3 ± 0.77.5 ± 0.9 ***
CREA (Umol/L)16.3 ± 3.615.1 ± 3.317.4 ± 3.320.8 ± 4.221.7 ± 4.421.7 ± 3.525.0 ± 3.5 **19.5 ± 3.720.1 ± 2.6
TBIL (Umol/L)5.2 ± 0.65.6 ± 0.85.4 ± 1.15.8 ± 1.35.7 ± 1.16.1 ± 0.66.6 ± 1.06.4 ± 1.17.6 ± 1.7 *
GLU (mmol/L)4.0 ± 0.72.9 ± 0.83.4 ± 0.43.5 ± 0.73.3 ± 0.72.9 ± 0.73.6 ± 0.23.6 ± 0.63.5 ± 0.5
CHOL (mmol/L)1.6 ± 0.21.7 ± 0.31.8 ± 0.21.8 ± 0.11.7 ± 0.21.8 ± 0.11.9 ± 0.21.8 ± 0.31.9 ± 0.3 *
TG (mmol/L)0.5 ± 0.10.5 ± 0.10.4 ± 0.10.6 ± 0.10.5 ± 0.10.7 ± 0.10.6 ± 0.10.5 ± 0.10.4 ± 0.0
TP (g/L)57.3 ± 5.864.1 ± 3.765.5 ± 5.663.7 ± 1.460.6 ± 3.163.5 ± 5.266.0 ± 4.167.3 ± 5.372.4 ± 4.8
ALB (g/L)36.4 ± 1.840.9 ± 1.641.5 ± 2.540.0 ± 1.139.0 ± 1.540.3 ± 2.441.4 ± 1.742.9 ± 2.945.2 ± 1.5
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine (CREA), total bilirubin (TBIL), glucose (GLU), total cholesterol (TC), triglycerides (TG), total protein (TP) and albumin (ALB). * Significantly different from Control group (p < 0.05). ** Significantly different from Control group (p < 0.01). *** Significantly different from Control group (p < 0.001).
Table
Table 6. Organ weights and Organ index of rats with 90-day repeated administration of rhizome and fibrous roots of C. dahurica.
Table 6. Organ weights and Organ index of rats with 90-day repeated administration of rhizome and fibrous roots of C. dahurica.
GroupControlRHFRC
0LDMDHDUHDLDMDHDUHD
Females
Heart (g)0.9 ± 0.120.88 ± 0.060.88 ± 0.090.89 ± 0.071.19 ± 0.351.04 ± 0.150.91 ± 0.081.00 ± 0.201.05 ± 0.20
(%BW)0.36 ± 0.020.33 ± 0.020.33 ± 0.050.34 ± 0.010.38 ± 0.070.39 ± 0.080.35 ± 0.040.38 ± 0.080.38 ± 0.08
Liver (g)5.56 ± 0.585.56 ± 0.495.25 ± 0.277.55 ± 0.448.87 ± 1.287.90 ± 1.577.99 ± 1.107.89 ± 1.157.66 ± 1.10
(%BW)2.24 ± 0.172.12 ± 0.171.96 ± 0.182.93 ± 0.243.21 ± 0.462.87 ± 0.403.09 ± 0.382.99 ± 0.412.81 ± 0.46
Spleen(g)0.43 ± 0.060.50 ± 0.100.46 ± 0.070.59 ± 0.070.53 ± 0.120.45 ± 0.100.53 ± 0.080.49 ± 0.090.55 ± 0.07
(%BW)0.17 ± 0.010.19 ± 0.050.17 ± 0.020.23 ± 0.040.19 ± 0.050.17 ± 0.030.21 ± 0.040.19 ± 0.030.20 ± 0.03
Lung(g)1.27 ± 0.471.16 ± 0.131.02 ± 0.111.03 ± 0.111.20 ± 0.071.48 ± 0.361.14 ± 0.051.41 ± 0.601.23 ± 0.15
(%BW)0.52 ± 0.220.44 ± 0.050.38 ± 0.050.40 ± 0.050.44 ± 0.030.56 ± 0.150.44 ± 0.040.53 ± 0.220.45 ± 0.07
Kidney(g)1.72 ± 0.161.64 ± 0.191.57 ± 0.141.74 ± 0.192.04 ± 0.201.96 ± 0.201.28 ± 0.721.87 ± 0.141.86 ± 0.24
(%BW)0.70 ± 0.070.62 ± 0.060.58 ± 0.050.67 ± 0.040.74 ± 0.070.74 ± 0.100.66 ± 0.040.71 ± 0.030.68 ± 0.09
Stomach(g)1.59 ± 0.271.35 ± 0.101.49 ± 0.111.37 ± 0.251.48 ± 0.271.54 ± 0.151.43 ± 0.121.48 ± 0.091.63 ± 0.26
(%BW)0.64 ± 0.070.51 ± 0.040.56 ± 0.060.53 ± 0.090.54 ± 0.090.58 ± 0.050.55 ± 0.030.56 ± 0.040.59 ± 0.07
Brain (g)1.67 ± 0.151.77 ± 0.261.74 ± 0.091.79 ± 0.161.74 ± 0.171.48 ± 0.561.62 ± 0.141.74 ± 0.161.72 ± 0.21
(%BW)0.68 ± 0.110.67 ± 0.100.65 ± 0.070.69 ± 0.080.63 ± 0.080.62 ± 0.100.63 ± 0.040.66 ± 0.040.63 ± 0.08
Adrenal gland(g)0.18 ± 0.270.08 ± 0.010.07 ± 0.010.07 ± 0.010.10 ± 0.030.08 ± 0.010.08 ± 0.010.08 ± 0.010.09 ± 0.03
(%BW)0.03 ± 0.000.03 ± 0.000.03 ± 0.010.03 ± 0.000.04 ± 0.010.03 ± 0.010.03 ± 0.000.03 ± 0.000.03 ± 0.01
Thymus(g)0.23 ± 0.120.22 ± 0.060.21 ± 0.040.17 ± 0.040.21 ± 0.070.24 ± 0.120.17 ± 0.050.16 ± 0.030.25 ± 0.05
(%BW)0.09 ± 0.040.08 ± 0.020.08 ± 0.020.07 ± 0.010.08 ± 0.030.09 ± 0.050.06 ± 0.020.06 ± 0.010.09 ± 0.02
Genitals(g)0.63 ± 0.170.69 ± 0.200.46 ± 0.080.56 ± 0.090.70 ± 0.280.82 ± 0.390.46 ± 0.050.59 ± 0.220.67 ± 0.12
(%BW)0.25 ± 0.060.26 ± 0.070.17 ± 0.030.22 ± 0.020.25 ± 0.100.31 ± 0.160.18 ± 0.030.22 ± 0.080.24 ± 0.05
Males
Heart (g)1.31 ± 0.101.29 ± 0.101.38 ± 0.159.51 ± 0.811.32 ± 0.121.35 ± 0.101.34 ± 0.141.36 ± 0.081.33 ± 0.24
(%BW)0.32 ± 0.030.30 ± 0.010.32 ± 0.030.28 ± 0.030.32 ± 0.040.31 ± 0.010.32 ± 0.020.26 ± 0.140.32 ± 0.05
Liver (g)7.93 ± 0.537.77 ± 0.657.49 ± 1.029.51 ± 0.8110.68 ± 1.4410.19 ± 2.2311.13 ± 1.0110.53 ± 0.8112.03 ± 2.93
(%BW)1.91 ± 0.071.82 ± 0.151.72 ± 0.162.17 ± 0.132.59 ± 0.432.33 ± 0.352.65 ± 0.162.52 ± 0.112.92 ± 0.55
Spleen(g)0.54 ± 0.040.56 ± 0.100.63 ± 0.100.59 ± 0.090.67 ± 0.120.68 ± 0.190.64 ± 0.120.64 ± 0.130.71 ± 0.11
(%BW)0.36 ± 0.050.31 ± 0.020.32 ± 0.040.14 ± 0.030.16 ± 0.020.16 ± 0.040.33 ± 0.040.31 ± 0.010.41 ± 0.13
Lung(g)1.50 ± 0.271.32 ± 0.131.39 ± 0.181.42 ± 0.211.72 ± 0.951.60 ± 0.341.40 ± 0.171.28 ± 0.131.71 ± 0.64
(%BW)0.13 ± 0.010.13 ± 0.030.14 ± 0.020.32 ± 0.040.42 ± 0.270.37 ± 0.060.15 ± 0.020.15 ± 0.030.17 ± 0.02
Kidney(g)2.60 ± 0.242.71 ± 0.242.59 ± 0.152.67 ± 0.252.90 ± 0.282.85 ± 0.462.83 ± 0.182.85 ± 0.282.87 ± 0.36
(%BW)0.63 ± 0.050.64 ± 0.050.59 ± 0.040.61 ± 0.040.70 ± 0.080.65 ± 0.070.67 ± 0.020.68 ± 0.070.70 ± 0.04
Stomach(g)1.69 ± 0.361.63 ± 0.381.79 ± 0.301.88 ± 0.261.89 ± 0.151.81 ± 0.232.00 ± 0.442.18 ± 0.232.02 ± 0.19
(%BW)0.40 ± 0.060.38 ± 0.080.41 ± 0.070.43 ± 0.050.46 ± 0.040.42 ± 0.040.48 ± 0.110.52 ± 0.040.50 ± 0.03
Brain (g)1.75 ± 0.301.89 ± 0.131.85 ± 0.181.90 ± 0.121.70 ± 0.511.72 ± 0.381.94 ± 0.101.80 ± 0.241.83 ± 0.29
(%BW)0.42 ± 0.060.43 ± 0.040.43 ± 0.040.44 ± 0.030.41 ± 0.120.45 ± 0.020.41 ± 0.090.43 ± 0.060.45 ± 0.07
Adrenal gland(g)0.06 ± 0.020.07 ± 0.020.06 ± 0.020.06 ± 0.010.07 ± 0.020.05 ± 0.000.07 ± 0.010.06 ± 0.020.06 ± 0.02
(%BW)0.01 ± 0.000.02 ± 0.000.01 ± 0.000.01 ± 0.000.02 ± 0.010.01 ± 0.000.02 ± 0.000.01 ± 0.000.01 ± 0.01
Thymus(g)0.18 ± 0.100.26 ± 0.080.16 ± 0.080.14 ± 0.050.21 ± 0.120.26 ± 0.110.19 ± 0.070.19 ± 0.030.02 ± 0.08
(%BW)0.04 ± 0.020.06 ± 0.020.04 ± 0.020.03 ± 0.010.05 ± 0.030.06 ± 0.020.05 ± 0.020.04 ± 0.010.04 ± 0.03
Genitals(g)3.32 ± 0.262.91 ± 0.303.15 ± 0.223.32 ± 0.363.07 ± 0.243.16 ± 0.163.18 ± 0.082.75 ± 1.132.98 ± 0.35
(%BW)0.80 ± 0.060.73 ± 0.090.68 ± 0.090.76 ± 0.090.73 ± 0.070.76 ± 0.040.73 ± 0.080.77 ± 0.030.73 ± 0.11
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Yu, Y.; Tan, J.; Nie, J.; Lv, C.; Lu, J. Fibrous Roots of Cimicifuga Are at Risk of Hepatotoxicity. Molecules 2022, 27, 938. https://doi.org/10.3390/molecules27030938

AMA Style

Yu Y, Tan J, Nie J, Lv C, Lu J. Fibrous Roots of Cimicifuga Are at Risk of Hepatotoxicity. Molecules. 2022; 27(3):938. https://doi.org/10.3390/molecules27030938

Chicago/Turabian Style

Yu, Yang, Jialiang Tan, Jianing Nie, Chongning Lv, and Jincai Lu. 2022. "Fibrous Roots of Cimicifuga Are at Risk of Hepatotoxicity" Molecules 27, no. 3: 938. https://doi.org/10.3390/molecules27030938

Article Metrics

Back to TopTop